Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2010

Open Access 01-12-2010 | Research

Deregulation of apoptosis mediators' p53 and bcl2 in lung tissue of COPD patients

Authors: Marianna Siganaki, Anastasios V Koutsopoulos, Eirini Neofytou, Eleni Vlachaki, Maria Psarrou, Nikolaos Soulitzis, Nikolaos Pentilas, Sophia Schiza, Nikolaos M Siafakas, Eleni G Tzortzaki

Published in: Respiratory Research | Issue 1/2010

Login to get access

Abstract

Abnormal apoptotic events in chronic obstructive pulmonary disease (COPD) subvert cellular homeostasis and may play a primary role in its pathogenesis. However, studies in human subjects are limited.
p53 and bcl2 protein expression was measured by western blot on lung tissue specimens from 43 subjects (23 COPD smokers and 20 non-COPD smokers), using beta-actin as internal control. Additionally, p53 and bcl2 expression patterns were evaluated by immunohistochemistry in formalin-fixed, paraffin-embedded lung tissue sections from the same individuals.
Western blot analysis showed statistically significant increased p53 protein levels in COPD smokers in comparison with non-COPD smokers (p = 0.038), while bcl2 protein levels were not statistically different between the two groups. Lung immunohistochemistry showed increased ratio of positive p53-stained type II pneumocytes/total type II pneumocytes in COPD smokers compared to non-COPD smokers (p = 0.01), whereas the p53 staining ratio in alveolar macrophages and in lymphocyte-like cells did not differ statistically between the two groups. On the other hand, bcl2 expression did not differ between the two groups in all three cell types.
The increased expression of pro-apoptotic p53 in type II pneumocytes of COPD patients not counterbalanced by the anti-apoptotic bcl2 could reflect increased apoptosis in the alveolar epithelium of COPD patients. Our results confirm previous experiments and support the hypothesis of a disturbance in the balance between the pro- and anti-apoptotic mediators in COPD.
Literature
1.
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J, Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. GOLD executive summary. Am J Respir Crit Care Med 2007,176(6):532–55.CrossRefPubMed
2.
Hodge S, Hodge G, Holmes M, Reynolds P: Increased peripheral blood T-cell apoptosis and decreased Bcl-2 in chronic obstructive pulmonary disease. Immunology and Cell Biology 2005, 83:160.CrossRefPubMed
3.
Hodge S, Hodge G, Holmes M, Reynolds PN: Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005,25(3):447–54.CrossRefPubMed
4.
Plataki M, Tzortzaki E, Rytila P, Makris D, Koutsopoulos A, Siafakas NM: Apoptotic mechanisms in the pathogenesis of COPD. Internat J COPD 2006,1(2):161–171.CrossRef
5.
6.
Hodge S, Hodge G, Holmes M, et al.: Apoptosis in COPD. Curr Respir Med Reviews 2005, 1:33–41.CrossRef
7.
Park JW, Ryter SW, Choi AM: Functional significance of apoptosis in chronic obstructive pulmonary disease. COPD 2007,4(4):347–53.CrossRefPubMed
8.
9.
Haupt S, Berger M, Goldberg Z, Haupt Y: Apoptosis - the p53 network. J Cell Sci 2003, 116:4077–85.CrossRefPubMed
10.
11.
Weaver CV, Liu S-P: Differentially expressed pro- and anti-apoptogenic genes in response to benzene exposure: Immunohistochemical localization of p53, Bag, Bad, Bax, Bcl-2 and Bcl-w in lung epithelia. Exper Toxicol Pathol 2008, 59:265–272.CrossRef
12.
Tzortzaki E, Siafakas N: A new hypothesis for the initiation of COPD. Eur Resp J 2009,34(2):310–5.CrossRef
13.
14.
Kasahara Y, Tuder RM, Cool CD, et al.: Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001, 163:737–744.CrossRefPubMed
15.
Tuder RM, Zhen L, Cho CY, et al.: Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003, 29:88–97.CrossRefPubMed
16.
Hodge S, Hodge G, Holmes M, et al.: Apoptosis in COPD. Current Respiratory Medicine Reviews 2005, 1:33–41.CrossRef
17.
Jiménez-Ruiz C, Miravitlles M, Sobradillo V, Gabriel R, Viejo JL, Masa JF, Fernández-Fau L, Villasante C: Can cumulative tobacco consumption, FTND score, and carbon monoxide concentration in expired air be predictors of chronic obstructive pulmonary disease? Nicotine Tob Res 2004,6(4):649–53.CrossRefPubMed
18.
Vlachaki EM, Koutsopoulos AV, Tzanakis N, Neofytou E, Siganaki M, Drositis I, Moniakis A, Schiza S, Siafakas NM, Tzortzaki EG: Altered surfactant protein-A (SP-A) expression in type II pneumocytes in COPD. Chest 2010,137(1):37–45.CrossRefPubMed
19.
Mascaretti RS, Mataloun MM, Dolhnikoff M, Rebello CM: Lung morphometry, collagen and elastin content: changes after hyperoxic exposure in preterm rabbits. Clinics 2009,64(11):1099–104.CrossRefPubMedPubMedCentral
20.
Ikeda K, Monden T, Kanoh T, Tsujie M, Izawa H, Haba A, Ohnishi T, Sekimoto M, Tomita N, Shiozaki H, Monden M: Extraction and Analysis of Diagnostically Useful Proteins from Formalin-fixed, Paraffin-embedded Tissue Sections. J Histochem Cytochem 1998, 46:397–403.CrossRefPubMed
21.
Hodge S, Hodge G, Scicchitano R, et al.: Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 2003, 81:289–296.CrossRefPubMed
22.
Bratton DL, Henson PM: Autoimmunity and apoptosis: refusing to go quietly. Nat Med 2005, 11:26–27.CrossRefPubMed
23.
24.
Weaver CV, Liu SP, Lu JF, Lin BS: The effects of benzene exposure on apoptosis in epithelial lung cells: localization by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) and the immunocytochemical localization of apoptosis-related gene products. Cell Biol Toxicol 2007,23(3):201–20.CrossRefPubMed
25.
Imai K, Mercer BA, Schulman LL, Sonett JR, D'Armiento JM: Correlation of lung surface area to apoptosis and proliferation in human emphysema. Eur Respir J 2005, 25:250–258.CrossRefPubMed
26.
Yokohori N, Aoshiba K, Nagai A: Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 2004, 125:626–632.CrossRefPubMed
27.
de Souza PM, Lindsay MA: Apoptosis as a therapeutic target for the treatment of lung diseases. Curr Opin Pharmacol 2005, 5:232–237.CrossRefPubMed
28.
Schleimer RP: Glucocorticoids Suppress Inflammation but Spare Innate Immune Responses in Airway Epithelium. Proc Am Thorac Soc 2004, 1:222–230.CrossRefPubMed
29.
Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J: Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009, 10:59.CrossRefPubMedPubMedCentral
30.
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008,359(15):1543–54.CrossRefPubMed
31.
Vignola AM, Riccobono L, Profita M, Foresi A, Di Giorgi R, Guerrera D, Gjomarkaj M, Di Blasi P, Paggiaro PL: Effects of low doses of inhaled fluticasone propionate on inflammation and remodelling in persistent-mild asthma. Allergy 2005,60(12):1511–7.CrossRefPubMed
32.
Alexis NE, Lay JC, Haczku A, Gong H, Linn W, Hazucha MJ, Harris B, Tal-Singer R, Peden DB: Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers. Environ Health Perspect 2008,116(6):799–805.CrossRefPubMedPubMedCentral
33.
Pahlavani MA, Vargas DA: Aging but not dietary restriction alters the activation-induced apoptosis in rat T cells. FEBS Lett 2001, 491:114–118.CrossRefPubMed
34.
Hodge S, Hodge G, Holmes M, Reynolds PN: Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005, 25:447–454.CrossRefPubMed
35.
Makris D, Vrekoussis T, Izoldi M, Alexandra K, Katerina D, Dimitris T, Michalis A, Tzortzaki E, Siafakas NM, Tzanakis N: Increased apoptosis of neutrophils in induced sputum of COPD patients. Respir Med 2009,103(8):1130–5.CrossRefPubMed
36.
Hodge SJ, Hodge GL, Reynolds PN, Scicchitano R, Holmes M: Increased production of TGF-beta and apoptosis of T lymphocytes isolated from peripheral blood in COPD. Am J Physiol Lung Cell Mol Physiol 2003,285(2):L492–9.CrossRefPubMed
Metadata
Title
Deregulation of apoptosis mediators' p53 and bcl2 in lung tissue of COPD patients
Authors
Marianna Siganaki
Anastasios V Koutsopoulos
Eirini Neofytou
Eleni Vlachaki
Maria Psarrou
Nikolaos Soulitzis
Nikolaos Pentilas
Sophia Schiza
Nikolaos M Siafakas
Eleni G Tzortzaki
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2010
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-11-46

Other articles of this Issue 1/2010

Respiratory Research 1/2010 Go to the issue

Research

Inhibition of IFN-γ-dependent antiviral airway epithelial defense by cigarette smoke

Research

Inflammatory changes in the airways of mice caused by cigarette smoke exposure are only partially reversed after smoking cessation

Research

Pharmacological studies of the mechanism and function of interleukin-1β-induced miRNA-146a expression in primary human airway smooth muscle

Research

Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury

Research

Characterisation of COPD heterogeneity in the ECLIPSE cohort

Research

Inhibitors of inflammation and endogenous surfactant pool size as modulators of lung injury with initiation of ventilation in preterm sheep
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits